Hale and healthy

Friday, April 15, 2005

A new way of developing drugs for neglected diseases of the poor world
This week, scientists from the Institute for OneWorld Health, the first not-for-profit pharmaceutical company in America, presented the results of a large clinical trial at the Third World Congress on Leishmaniasis in Palermo, Italy. Leishmaniasis is a parasitic infection transmitted by the bite of a sand fly. The trial shows that an antibiotic called paromomycin is effective for treating the most dangerous version of the disease, visceral leishmaniasis, which affects 1.5m people around the world and kills 200,000 of them every year. Those data are obviously important for medical reasons. But they are also important as a demonstration that the institute’s novel approach to drug development is working.
Story found here.

Source: The Economist